



Wegovy®, Zepbound®, and Saxenda®

The following GLP-1 drugs are currently on the [Medi-Cal Rx Contract Drugs List](#) (CDL) and have a Code I diagnosis restriction of *Chronic Weight Management*. Effective January 1, 2026, these drugs will be removed from the CDL and will no longer be eligible for coverage for **weight loss** or **weight-loss indications**:

- Wegovy
- Zepbound
- Saxenda

Effective January 1, 2026, claims for these three drugs will deny with **Reject Code 70 – Product/Service Not Covered** regardless of indication, and previously approved prior authorizations (PAs) will expire. PA requests for these drugs will be considered in the following situations:

- Wegovy when used for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) or cardiovascular disease
- Zepbound when used for obstructive sleep apnea (OSA)

Other GLP-1 Drugs

The following GLP-1 drugs are currently on the CDL and will continue to have a Code I diagnosis restriction of type 2 diabetes. Effective January 1, 2026, these drugs will no longer be eligible for coverage for **weight loss** or **weight-loss indications**:

- Ozempic®
- Rybelsus®
- Mounjaro®
- Victoza®
- Byetta
- Bydureon®
- Trulicity® (*Code I diagnosis restriction will be effective January 1, 2026*)

Claims for these seven drugs will continue to deny with **Reject Code 80 – Diagnosis Code Submitted Does Not Meet Drug Coverage Criteria** when the Code I diagnosis restriction is not met. PA requests submitted for non-weight loss indications will be reviewed for coverage consideration based on medical necessity.

Note: Effective January 1, 2026, PA requests submitted for weight loss or weight loss indications will be reviewed for medical necessity for members younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.